Application of Meso Scale Discovery (MSD) ELISA Kit in Insulin Detection

There is increasing evidence that events occurring during the fetal and early life stages may lead to permanent metabolic changes such as type 2 diabetes and metabolic syndrome [a risk factor that increases the risk of heart disease, diabetes and stroke) The combination]. Although studies in children and adults support the hypothesis that preterm birth may lead to poor metabolic changes, it is unclear whether the observed relationship between preterm birth and future insulin resistance and type 2 diabetes originates from prenatal [ Changes in insulin metabolism when the fetus is in the uterus] or early childhood.

The researchers found that plasma insulin concentrations were negatively correlated with gestational age in newborn babies and children in early childhood. At birth, the average insulin concentration for term infants (≥ 39 weeks) was 9.2 μIU/mL (micro-international units per milliliter), and preterm infants (<34 weeks) were 18.9 μIU/mL. In early childhood, randomized plasma insulin concentrations were higher in early term, late preterm, and early preterm infants than those born in full-term. "These findings provide more evidence for future insulin resistance and a risk factor for type 2 diabetes," the researchers said. "These findings may be a risk factor for future insulin resistance and type 2 diabetes."

It can be seen from the above that the conclusions of insulin research are often in international units (such as μIU/mL). The conclusions of such data are compared with the horizontal comparison. The international unit is also the customary unit for clinical diagnosis of hospitals. In the scientific research of metabolic diseases, the detection of rat/mouse insulin (Mouse/Rat Insulin) ELISA kit, but does not support international unit conversion, and insufficient sensitivity limits scientific research findings.

Comparison of Mouse/Rat Insulin Kits

Comparison of Human Insulin Kits

Meso Scale Discovery (MSD), USA : Founded in 1995, it was the first in the world to detect human-borne H1N1 virus in 2009. In 2013, it was named “the top five immunoassay brand in the world”. The microplate-based electrochemiluminescence detection technology (referred to as microplate ECL) developed by the company is a third-generation immunoassay technology for comprehensive upgrade/substitution ELISA, Western Blot and multi-protein factor detection. Has been widely used by pharmaceutical research and development centers, drug safety evaluation centers, GLP laboratories, contract outsourcing companies (CRO), diagnostics, biotechnology companies for drug screening, animal models, drug metabolism, blood drug concentration, immunogenicity, neutralization Experiments, Biomarker Screening, Antibody Affinity, Vaccine Evaluation, Host Cell Residues, Diagnostic Studies.

US Meso Scale Discovery (MSD) part of the application direction:

1. Cytokine research: A multi-factor study was performed with a conventional sensitivity of 0.05 pg/ml. Multi-factor detection that meets GLP requirements.

2. Signal pathway research: A simultaneous study of Phospho/Total phosphorylated protein can be performed in just 4.5 hours.

3, neurodegenerative disease research: the use of cerebrospinal fluid CSF and other complex matrix samples detection, no matrix effect.

4, drug safety assessment: Compliance with FDA standards for high-sensitivity multi-indicator testing.

5, immunogenicity assessment: compatible with up to 50ug / ml high concentration of blood drug interference, reaching <100ng / ml ADA detection sensitivity, in line with FDA requirements.

6, antibody subtype typing: rapid identification of different subtypes in the sample, up to 0.1 ng / ml sensitivity level

7. Antibody epitope analysis: Identification of up to 10 different epitopes at a time.

8. Multivalent vaccine titer assessment: shortened to 1.5 hours of assessment process.

9. Antibody Affinity Test: Affinity samples up to 10-15 can be analyzed based on the affinity determination of the SET methodology.

10. Neutralizing antibody assay: based on cell level, more in line with actual biological requirements.

11, cell level binding test: Cell Base Binding test, up to 6log linear range, can identify cell surface receptors and corresponding complement binding levels and affinity;

12, bioprocess residue determination: a single test, can identify a variety of host cells and a variety of protein residues in the purification process determination, the basic sensitivity of Yanak, to ensure the effectiveness of the identification.